In a small prospective study of 12 women with breast cancer, the measured plasma concentrations of endoxifen were decreased by around twofold 4 weeks after the beginning of paroxetine (SSRI) intake, which means that CYP2D6 mediates endoxifen metabolism [39]. The gene discussed is CYP2D6; the disease is breast carcinoma.